FDA Approves Sanofi Sarclisa Escena On-Body Injector

The FDA approved Sanofi’s subcutaneous Sarclisa Escena (isatuximab-irfc) on July 9, 2026, making it the first anticancer treatment approved for administration via an on-body injector. The approval covers all existing intravenous Sarclisa indications in multiple myeloma, spanning newly diagnosed patients and relapsed or refractory disease.

The device, called CirCLIQ and built on Enable Injections’ enFuse platform, delivers a fixed 1,400 mg dose subcutaneously with the push of a button. A retractable 30-gauge needle, thinner than those used for standard large-volume injections, minimizes patient discomfort. The FDA also approved manual subcutaneous administration, giving providers two options.

The IRAKLIA trial

The approval rests on the Phase 3 IRAKLIA study (NCT05405166), a randomized open-label non-inferiority trial comparing subcutaneous Sarclisa plus pomalidomide and dexamethasone (Pd) against IV Sarclisa-Pd in 531 relapsed or refractory multiple myeloma patients who had received at least one prior therapy.

• Objective response rate: 71.1% (187 of 263) with SC Sarclisa-Pd versus 70.5% (189 of 268) with IV Sarclisa-Pd, establishing non-inferiority (relative risk 1.008, 95% CI 0.903-1.126)
• Infusion-related reactions: 1.5% with SC versus 25% with IV, a dramatic reduction
• Injection site reactions: 0.4% of OBI injections (19 of 5,145), nearly all Grade 1

The FDA approval notice confirmed the review was based on comparable pharmacokinetics and safety between the SC and IV formulations.

Why the delivery method matters

Multiple myeloma is a cancer of plasma cells in the bone marrow that typically requires frequent clinic visits for IV infusions over months or years of treatment. An on-body injector lets patients receive therapy subcutaneously at home, eliminating chair time and reducing the infusion reactions that complicate IV administration. The 25% to 1.5% drop in systemic administration reactions is clinically meaningful for a patient population on long-term maintenance therapy.

For Sanofi, the innovation is the format, not the molecule. Sarclisa IV is already approved and competes with J&J’s Darzalex (daratumumab), the dominant CD38 antibody in myeloma. Subcutaneous Darzalex is available but uses manual injection, not an on-body device. Sarclisa Escena’s OBI could shift market share by improving patient convenience and reducing nurse burden in infusion centers. For background on how PDUFA dates structure the approval calendar these drugs launch into, see our PDUFA date guide.

What to watch next

The key risk is commercial uptake. Sanofi says more than 70,000 patients worldwide have received IV Sarclisa across four approved indications. Whether the OBI formulation converts IV patients and captures share from Darzalex depends on payor coverage and physician willingness to adopt a new delivery device. Watch whether this creates a template for other CD38 antibodies and oncology biologics, since Enable Injections’ enFuse platform is modality-agnostic.

SNY closed at $43.35 on July 23, with a market cap of approximately $104 billion. Sanofi trades as an American Depositary Receipt, with each ADS representing half an ordinary share. The Sarclisa franchise contributes to Sanofi’s oncology revenue, but at this valuation the stock is priced for its broader pipeline, including Dupixent.

Source: Sanofi press release | IRAKLIA trial on ClinicalTrials.gov

What It Means for the Trade

This is a format approval, not a drug approval, and the trade is in what the format unlocks commercially. Sarclisa is the distant challenger in CD38 myeloma — Darzalex’s franchise scale dwarfs it — and a first-in-oncology on-body injector gives Sanofi a convenience argument no CD38 competitor currently matches, since subcutaneous Darzalex requires manual injection and chair time. The IRAKLIA data makes the pitch concrete: equivalent efficacy, infusion reactions collapsing from 25% to 1.5%, and home administration possible. For long-term maintenance myeloma patients, that is a real quality-of-life differentiator oncologists and payers can price.

The realistic sizing: Escena converts existing IV Sarclisa patients first (retention, not conquest), then challenges Darzalex starts at the margin where convenience drives choice. It is unlikely to flip the franchise hierarchy, but it defends and modestly grows a several-hundred-million-dollar product inside Sanofi’s oncology stable — incremental, not thesis-changing, for a $104 billion ADR.

Mechanism and Market Context

The pharmacology: a fixed 1,400 mg subcutaneous dose with the enFuse on-body injector achieves comparable pharmacokinetics to IV infusion — the non-inferiority trial design (ORR 71.1% versus 70.5%) plus PK bridging is the standard formulation-switch approval pattern in oncology, the same playbook that converted daratumumab and rituximab to subcutaneous forms. The clinically meaningful gain is the infusion-reaction profile: IV monoclonals trigger cytokine-based reactions during the first hours of administration, and a 25% to 1.5% reduction removes the pre-medication, monitoring, and chair-time burden that makes IV maintenance therapy costly for clinics and patients alike.

The device itself — thin-gauge needle, large-volume subcutaneous delivery absorbed over time rather than bolus — is modality-agnostic technology. If Escena proves the commercial concept in oncology, watch for the enFuse platform appearing across other long-term injectable oncology and immunology brands; the first approval is the template that lowers the regulatory bar for the rest.

Risks and What Could Go Wrong

1. Adoption friction. Oncology infusion economics pay clinics for chair time; a therapy that removes chair time must survive revenue-model resistance from the same centers prescribing it.
2. J&J’s response. Darzalex could adopt on-body delivery via its own partnerships quickly, neutralizing the differentiation window.
3. Home-administration liability. Any safety event with at-home oncology dosing generates disproportionate headlines and slows the whole concept.
4. Niche size. Even on success, converting a challenger CD38 franchise’s growth profile does not move Sanofi’s $104 billion valuation — this is franchise defense, not a re-rating catalyst.

Net: clever format win with genuine patient benefit and modest financial stakes. Trade SNY on the pipeline story, not on CirCLIQ.